智翔金泰(688443) - 2025 Q4 - 年度业绩预告

Revenue Projections - The company expects 2025 annual revenue to be between 209.45 million and 250.88 million CNY, an increase of 179.35 million to 220.78 million CNY compared to the previous year, representing a growth of 595.96% to 733.62%[2] - The significant increase in revenue is primarily due to the steady growth in sales of the company's first commercialized product, the Saliqi monoclonal antibody injection, and revenue from the GR1803 injection licensing agreement[6] R&D Expenses - The estimated R&D expenses for 2025 are projected to be between 425.21 million and 519.70 million CNY, a decrease of 90.09 million to 184.58 million CNY from the previous year, reflecting a reduction of 14.77% to 30.27%[2] - The company maintains a high level of R&D investment as multiple products enter clinical research and core products reach critical clinical trial stages[6] Net Loss Projections - The expected net loss attributable to the parent company for 2025 is projected to be between -480.64 million and -587.45 million CNY, a reduction of 209.83 million to 316.64 million CNY compared to the previous year, indicating a decrease of 26.32% to 39.71%[2] - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be between -523.63 million and -630.44 million CNY, with a reduction of 173.89 million to 280.70 million CNY compared to the previous year, representing a decrease of 21.62% to 34.90%[3] Expense Management - The company will not incur share-based payment expenses in 2025 due to the expiration of the stock incentive plan for the core team implemented in 2022, contributing to reduced expenses[6] Financial Forecast Integrity - The financial data in this forecast is based on preliminary calculations by the company's finance department and has not yet been audited by a registered accountant[7] - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast[7]